Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome

Arthritis and Rheumatology

Volumn 68, Issue 4, 2016, Pages 977-985

  Nocturne, G ^a   Virone, A ^a   Ng, Wan Fai ^b   Le Guern, V ^c   Hachulla, E ^d   Cornec, D ^e   Daien, C ^f   Vittecoq, O ^g   Bienvenu, B ^h   Marcelli, C ^h   Wendling, D ⁱ   Amoura, Z ^j   Dhote, R ^k   Lavigne, C ^l   Fior, R ^m   Gottenberg, J E ⁿ   Seror, R ^a   Mariette, X ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIV LILLE   (France)

^e SERVICE DE RHUMATOLOGIE   (France)

^f MONTPELLIER UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ DE ROUEN   (France)

^h CHU CÔTE DE NACRE   (France)

ⁱ Université Bourgogne Franche Comté   (France)

^j SORBONNE UNIVERSITÉ   (France)

^k AVICENNE HOSPITAL   (France)

^l ANGERS UNIVERSITY HOSPITAL   (France)

^m HÔPITAL ANTOINE BÉCLÈRE   (France)

ⁿ UNIVERSITÉ DE STRASBOURG   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; RHEUMATOID FACTOR; RITUXIMAB; VINBLASTINE; COMPLEMENT COMPONENT C4;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CANCER SURGERY; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ACTIVITY; DISEASE DURATION; EUROPEAN LEAGUE AGAINST RHEUMATISM SJOGREN SYNDROME DISEASE ACTIVITY INDEX; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; INFLAMMATION; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; MUSCULOSKELETAL DISEASE ASSESSMENT; MYCOSIS FUNGOIDES; PREDICTION; PRIORITY JOURNAL; SJOEGREN SYNDROME; WATCHFUL WAITING; FRANCE; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LUNG NEOPLASMS; LYMPHOMA, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPENIA; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; SALIVARY GLAND NEOPLASMS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; SKIN NEOPLASMS; UNITED KINGDOM;

ADULT; AGED; CASE-CONTROL STUDIES; COMPLEMENT C4; CRYOGLOBULINEMIA; FEMALE; FRANCE; HODGKIN DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LUNG NEOPLASMS; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPENIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOSIS FUNGOIDES; RETROSPECTIVE STUDIES; RHEUMATOID FACTOR; SALIVARY GLAND NEOPLASMS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; SKIN NEOPLASMS; UNITED KINGDOM;

EID: 84962091368     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39518     Document Type: Article

References (37)

1. Zintzaras E, Voulgarelis M, Moutsopoulos HM., The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337-44.
2. Fallah M, Liu X, Ji J, Forsti A, Sundquist K, Hemminki K., Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol 2014. E-pub ahead of print.
3. Johnsen SJ, Brun JG, Goransson LG, Smastuen MC, Johannesen TB, Haldorsen K, et al., Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based study. Arthritis Care Res (Hoboken) 2013; 65: 816-21.
4. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al., Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98: 51-60.
5. Weng MY, Huang YT, Liu MF, Lu TH., Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren's syndrome in Taiwan. Ann Rheum Dis 2012; 71: 524-7.
6. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT., Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796-803.
7. Anaya JM, Correa PA, Mantilla RD, Arcos-Burgos M., TAP, HLA-DQB1, and HLA-DRB1 polymorphism in Colombian patients with primary Sjögren's syndrome. Semin Arthritis Rheum 2002; 31: 396-405.
8. Solans-Laque R, Lopez-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarres M., Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 2011; 41: 415-23.
9. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM., Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996; 39: 767-72.
10. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
11. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon (France): IARC Press; 2008.
12. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al, on behalf of the EULAR Sjögren's Task Force. EULAR Sjögren's Syndrome Disease Activity Index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010; 69: 1103-9.
13. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dorner T, et al, on behalf of the EULAR Sjögren's Task Force. Validation of EULAR primary Sjögren's Syndrome Disease Activity (ESSDAI) and Patient Indexes (ESSPRI). Ann Rheum Dis 2015; 74: 859-66.
14. Meiners P, Mariette X, Baron G, Vitali C, Bowman S, Gottenberg JE, et al., Développement d'un score ClinESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) sans domaine biologique: un outil pour les études biologiques. In: Proceedings of the Congress of the Société Française de Rhumatologie; 2014. p. 49.
15. Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, et al, on behalf of the EULAR Sjögren's Task Force. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's Syndrome Disease Activity (ESSDAI) and Patient-Reported Indexes (ESSPRI). Ann Rheum Dis 2014. E-pub ahead of print.
16. Gottenberg JE, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P, et al., Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome: data at enrollment in the prospective ASSESS cohort. PLoS One 2013; 8: e59868.
17. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM., Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000; 29: 296-304.
18. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM., Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009; 88: 284-93.
19. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM, and the Members of the European Concerted Action on Sjögren's Syndrome. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999; 42: 1765-72.
20. Routsias JG, Goules JD, Charalampakis G, Tzima S, Papageorgiou A, Voulgarelis M., Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum 2013; 43: 178-86.
21. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, et al., Lymphomas in patients with Sjögren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997; 90: 766-75.
22. Nocturne G, Mariette X., Sjögren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2015; 168: 317-27.
23. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al., Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-10.
24. Saadoun D, Pineton de Chambrun M, Hermine O, Karras A, Choquet S, Jego P, et al., Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res (Hoboken) 2013; 65: 643-7.
25. Zucca E, Conconi A, Laszlo D, Lopez-Guillermo A, Bouabdallah R, Coiffier B, et al., Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 2013; 31: 565-72.
26. Martel C, Gondran G, Launay D, Lalloue F, Palat S, Lambert M, et al., Active immunological profile is associated with systemic Sjögren's syndrome. J Clin Immunol 2011; 31: 840-7.
27. Quartuccio L, Isola M, Baldini C, Priori R, Bartoloni Bocci E, Carubbi F, et al., Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2014; 51: 75-80.
28. Nishishinya MB, Pereda CA, Munoz-Fernandez S, Pego-Reigosa JM, Rua-Figueroa I, Andreu JL, et al., Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis. Rheumatol Int 2015; 35: 17-26.
29. Martin T, Weber JC, Levallois H, Labouret N, Soley A, Koenig S, et al., Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 2000; 43: 908-16.
30. Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJ., Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005; 201: 1229-41.
31. Bende RJ, Slot LM, Hoogeboom R, Wormhoudt TA, Adeoye AO, Guikema JE, et al., Stereotypic rheumatoid factors that are frequently expressed in mucosa-associated lymphoid tissue-type lymphomas are rare in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheumatol 2015; 67: 1074-83.
32. Brito Zeron P, Kostov B, Solans R, de Luna G, Casanovas A, Diaz-Lopez B, et al., Association between systemic activity and lymphoma in primary Sjögren syndrome: baseline ESSDAI predictors in 921 Spanish patients (GEAS-SS Registry) [abstract]. Ann Rheum Dis 2014; 73 Suppl 2: 142.
33. Papageorgiou A, Ziogas DC, Mavragani CP, Zintzaras E, Tzioufas AG, Moutsopoulos HM, et al., Predicting the outcome of Sjögren's syndrome-associated non-Hodgkin's lymphoma patients. PLoS One 2015; 10: e0116189.
34. Gottenberg JE, Ravaud P, Puechal X, Le Guern V, Sibilia J, Goeb V, et al., Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014; 312: 249-58.
35. Fox RI, Dixon R, Guarrasi V, Krubel S., Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996; 5 Suppl 1: S31-6.
36. Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al., Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993; 52: 360-4.
37. Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae SC, et al., Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2015; 74: 1530-6.